Tsai, Donald E <br/><br/>
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2008 
 - 5619-25 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-5185  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Bexarotene<br/>Female<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Leukemia, Promyelocytic, Acute--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Retinoid X Receptors--antagonists & inhibitors<br/>Tetrahydronaphthalenes--administration & dosage